Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Rieckmann

Showing results (91-100 of 129) with videos related to

Pageof 13
Sort By:
Journal of Neurology|December 25, 2012
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY studyGiancarlo Comi, Stuart D Cook, Gavin Giovannoni, et al.
Cytokine|August 12, 2004
Evaluation of diagnostic relevance of mRNA levels in peripheral blood: predictive value for mortality in hemodialysis patientsReiner Füth, Christian Herder, Stefan Förster, et al.
The New England Journal of Medicine|January 22, 2010
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosisGavin Giovannoni, Giancarlo Comi, Stuart Cook, et al.
Nature Medicine|June 4, 2002
CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammationRalf A Linker, Mathias Mäurer, Stefanie Gaupp, et al.
Neurodegenerative Disease Management|October 24, 2022
Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summaryPeter Rieckmann, Diego Centonze, Gavin Giovannoni, et al.
Therapeutic Advances in Neurological Disorders|December 13, 2021
Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practicePeter Rieckmann, Diego Centonze, Gavin Giovannoni, et al.
Clinical Drug Investigation|October 25, 2011
Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY StudyShehzad Ali, Noman Paracha, Stuart Cook, et al.
Journal of Neurology|September 1, 2012
Future MS care: a consensus statement of the MS in the 21st Century Steering GroupPeter Rieckmann, Alexey Boyko, Diego Centonze, et al.
Neurology and Therapy|November 5, 2025
Guiding Multiple Sclerosis Care: An Update to the 2013 Consensus Statement from the MS in the 21st Century Steering GroupRaed Alroughani, Elisabeth G Celius, Helen Gray, et al.
Journal of the Neurological Sciences|May 31, 2011
Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trialJoost Smolders, Raymond Hupperts, Frederik Barkhof, et al.
Pageof 13

Showing results (91-100 of 129) with videos related to

Sort By:
Pageof 13
Journal of Neurology|December 25, 2012
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY studyGiancarlo Comi, Stuart D Cook, Gavin Giovannoni, et al.
Cytokine|August 12, 2004
Evaluation of diagnostic relevance of mRNA levels in peripheral blood: predictive value for mortality in hemodialysis patientsReiner Füth, Christian Herder, Stefan Förster, et al.
The New England Journal of Medicine|January 22, 2010
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosisGavin Giovannoni, Giancarlo Comi, Stuart Cook, et al.
Nature Medicine|June 4, 2002
CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammationRalf A Linker, Mathias Mäurer, Stefanie Gaupp, et al.
Neurodegenerative Disease Management|October 24, 2022
Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summaryPeter Rieckmann, Diego Centonze, Gavin Giovannoni, et al.
Therapeutic Advances in Neurological Disorders|December 13, 2021
Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practicePeter Rieckmann, Diego Centonze, Gavin Giovannoni, et al.
Clinical Drug Investigation|October 25, 2011
Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY StudyShehzad Ali, Noman Paracha, Stuart Cook, et al.
Journal of Neurology|September 1, 2012
Future MS care: a consensus statement of the MS in the 21st Century Steering GroupPeter Rieckmann, Alexey Boyko, Diego Centonze, et al.
Neurology and Therapy|November 5, 2025
Guiding Multiple Sclerosis Care: An Update to the 2013 Consensus Statement from the MS in the 21st Century Steering GroupRaed Alroughani, Elisabeth G Celius, Helen Gray, et al.
Journal of the Neurological Sciences|May 31, 2011
Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trialJoost Smolders, Raymond Hupperts, Frederik Barkhof, et al.
Pageof 13